535 related articles for article (PubMed ID: 25293362)
1. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
[TBL] [Abstract][Full Text] [Related]
2. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and predictors of hand involvement in Thai patients with systemic sclerosis.
Wangkaew S; Sivasomboon C; Leungwatthananon W; Kasitanon N; Louthrenoo W
Int J Rheum Dis; 2018 Jan; 21(1):240-248. PubMed ID: 27456855
[TBL] [Abstract][Full Text] [Related]
4. Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study.
Kranenburg P; van den Hombergh WM; Knaapen-Hans HK; van den Hoogen FH; Fransen J; Vonk MC
Rheumatology (Oxford); 2016 Nov; 55(11):2001-2008. PubMed ID: 27520796
[TBL] [Abstract][Full Text] [Related]
5. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
6. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
7. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma.
Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S
Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
Heijnen IA; Foocharoen C; Bannert B; Carreira PE; Caporali R; Smith V; Kumánovics G; Becker MO; Vanthuyne M; Simsek I; Bocelli-Tyndall C; Walker UA
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):96-102. PubMed ID: 23101460
[TBL] [Abstract][Full Text] [Related]
9. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
[TBL] [Abstract][Full Text] [Related]
10. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
[TBL] [Abstract][Full Text] [Related]
11. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
12. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
[TBL] [Abstract][Full Text] [Related]
13. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.
Zanatta E; Huscher D; Ortolan A; Avouac J; Airò P; Balbir-Gurman A; Siegert E; Matucci Cerinic M; Cozzi F; Riemekasten G; Hoffmann-Vold AM; Distler O; Gabrielli A; Heitmann S; Hunzelmann N; Montecucco C; Morovic-Vergles J; Ribi C; Doria A; Allanore Y;
Rheumatology (Oxford); 2022 Nov; 61(12):4786-4796. PubMed ID: 35348643
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study.
Foocharoen C; Peansukwech U; Mahakkanukrauh A; Suwannaroj S; Pongkulkiat P; Khamphiw P; Nanagara R
Int J Rheum Dis; 2020 Jul; 23(7):945-957. PubMed ID: 32420701
[TBL] [Abstract][Full Text] [Related]
16. Increased Frequency of Activated Switched Memory B Cells and Its Association With the Presence of Pulmonary Fibrosis in Diffuse Cutaneous Systemic Sclerosis Patients.
Simon D; Balogh P; Erdő-Bonyár S; Böröcz K; Minier T; Czirják L; Berki T
Front Immunol; 2021; 12():686483. PubMed ID: 34276673
[TBL] [Abstract][Full Text] [Related]
17. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.
Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y;
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):68-75. PubMed ID: 30277860
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma.
Foocharoen C; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
Int J Rheum Dis; 2016 Sep; 19(9):913-23. PubMed ID: 27126733
[TBL] [Abstract][Full Text] [Related]
19. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
[TBL] [Abstract][Full Text] [Related]
20. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
